A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.
Farshid Dayyani, MD, PhD
Advertisement
Articles by Farshid Dayyani, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?
2
Cevostamab May Fill Gap in Multiple Myeloma Armamentarium
3
131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)
4
ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency
5